Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients

BACKGROUND: This meta-analysis aimed to test the hypothesis that the HER2-positive metastatic breast cancer (mBC) patients treated with anti-HER2 antibodies in trial intervention arms have a greater prolongation of overall survival (OS) than of progression-free survival (PFS) and this extra-prolonga...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast
Autors principals: Chen, I-Chun, Hu, Fu-Chang, Lin, Ching-Hung, Huang, Shu-Min, Chang, Dwan-Ying, Cheng, Ann-Lii, Lu, Yen-Shen
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2021
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8321956/
https://ncbi.nlm.nih.gov/pubmed/34298300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.breast.2021.07.006
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars